Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels.
Experience with anidulafungin against Candida krusei is limited. Immunosuppressed mice were injected with 1.3 x 10(7) to 1.5 x 10(7) CFU of C. krusei. Animals were treated with saline, 40 mg/kg fluconazole, 1 mg/kg amphotericin B, or 10 and 20 mg/kg anidulafungin for 5 days. Anidulafungin improved survival and significantly reduced the number of CFU/g in kidneys and serum beta-glucan levels.
Ostrosky-Zeichner
Luis
L
Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, Texas 77030, USA. Luis.Ostrosky-Zeichner@uth.tmc.edu
Paetznick
Victor L
VL
Rodriguez
Jose
J
Chen
Enuo
E
Sheehan
Daniel J
DJ
D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000302:isolation & purification*; D002177:Candidiasis / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D004195:Disease Models, Animal; D054714:Echinocandins / Q000627:therapeutic use*; D007668:Kidney / Q000382:microbiology; D008297:Male; D051379:Mice; D047071:beta-Glucans / Q000097:blood*
D000935:Antifungal Agents; D054714:Echinocandins; D047071:beta-Glucans; C033363:beta-1,3-glucan; D000077612:Anidulafungin